LPBI Group’s Vision is dynamically undated at the following LINKS:
2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets
TO BE UPDATED on 1/5/2019
https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/
https://pharmaceuticalintelligence.com/gde-news/
https://pharmaceuticalintelligence.com/calendar/
LPBI Group has Three Enterprise Types and Five Subsidiaries
We are in the Professional Services Sector: e-Scientific Information Creation and Intellectual Property Assets Management:
Subsidiary #1: electronic Scientific Media or Scientific Digital Media – LPBI
and
Subsidiary #4: We are intermediaries for Commercialization, Licensing, Sales Outright of US Patents, representing Two inventors in Medical Devices
We are in Research Biotech Businesses
Subsidiary #3: R&D in 3D BioPrinting
FUNDING needs: $20Million [If VAR considered: $40Million]
and
Subsidiary #5: R&D in Drug Discovery
FUNDING needs: $20Million
We are in the Financial Transaction Sector (No Securities Traded):
Subsidiary #2: Deals, Funding and Partnerships
- MEDICAL DEVICES
- Informational PLATFORMS
- INVENTIONS IN BIOLOGICS
In Preparation: VB Profile
http://pages.vbprofiles.com/TheMostPopularLists
LPBI Group runs by:
Aviva Lev-Ari, PhD, RN – Founder of e-Scientific Media Enterprise (2012) and the LPBI Group (2016)
CORE VALUES
Leadership quality of our Team members:
Straightforward and Transparent, Honest and Trustworthy, Ethical and Principled, Authentic, Focused, Determined, Realistic, Decisive and Action-oriented, Accountable, Fair and Open-minded, Knowledgeable and Experienced, Consistent and Dependable, Confident and Optimistic, Insightful, discerning, Passionate, Empathetic and Selfless, Flexible, Humble, Courageous, Reciprocity, Hardworking.
Since LPBI Group’s IP is unencumbered, commercialization of US Patents is rendered to Funding rather than to litigation. Our Platform is accessible only to members of the Team in the Three Enterprise Type consisting of five subsidiaries that follow our Core values:
- deep Expertise
- shake of hand instead of 21 page contracts
- venture wellbeing comes first, personnel wellbeing is derived only from a healthy venture
- full transparency with the Team and with Investors
- loyalty to Management, to each Team member and daily adherence to Business Etiquette
- Team Playing is key — pushing back is not acceptable
STRATEGIC PLAN for LPBI Group (Draft)
What’s Part of LPBI Group?
MATERIAL BELOW THIS POINT IS UNDER CONSTRUCTION
HIGHLIGHTS
Subsidiary #1: Leaders in Pharmaceutical Business Intelligence
Scientific Digital Media
LPBI
- Open Access Online Scientific Journal – IP by Our Team
http://pharmaceuticalintelligence.com
- e-Books: WE ARE ON AMAZON.COM – IP by Our Team
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
- Biotech Conferences – Real Time Press Coverage of Biotech and Medicine Conferences
IP by Aviva and Dr. Williams.
By 12/2016 will be a candidate to consider M&A
Subsidiary #2: Deals, Funding & Partnerships
DFP
Funding Early Stage Biotech: IP by others
- Biologics or
- Medical Devices.
Average investment needed per venture $10Million and above
Subsidiary #3: Medical 3D BioPrinting
M3DP
Team of 15 – IP by Our Team
- Aviva manages R&D by the Team creating IP for a Pipeline of Medical Applications using 3D BioPrinting in two specialty departments:
- R&D in Tissue Engineering, Gene Therapy: Stem Cells and Gene Editing and Drug dosing and printing
- R&D in BioMEMS, Programmable Sensors and Medical Devices
- Gerard manages development of VARS of BioPrinters and BioInks
Funding needs: $20Million
Subsidiary #4: U.S. and Int’l Patents – Commercialization, Licensing and Sales
USPat
IP by Patent Holders
- Funding needed to commercialize,
- Partnerships to license
- Buyers for Sales of IP of Two Team members:
(a) to “corporate accounts”
(b) to “IP and Technology Patents Fund Managers”
Subsidiary #5: Joint Ventures for Intellectual Property Development
JVIP
SBH & M3DP (same Team as Subsidiary #3) – IP by Our Team
- Aviva manages R&D conducted by these two organizations created by a collaborative effort, creation of a pipeline of product concepts
- Seeking Funding of $20Milllion